20734-30-9

Usage

Uses

Used in Pharmaceutical Industry:
1-METHYL-4-HYDROXY-PIPERIDINE-4-CARBONITRILE serves as a crucial intermediate in the synthesis of a variety of drugs and compounds. Its distinctive chemical structure and properties contribute to the development of medications for a broad spectrum of conditions, making it an essential component in the advancement of pharmaceutical research and drug discovery.
Used in Chemical Research and Development:
Due to its unique chemical structure and properties, 1-METHYL-4-HYDROXY-PIPERIDINE-4-CARBONITRILE also finds applications in chemical research and development. It can be utilized to explore new chemical reactions, synthesize novel compounds, and potentially uncover new applications in various fields, further expanding its utility beyond the pharmaceutical industry.

InChI:InChI=1/C7H12N2O/c1-9-4-2-7(10,6-8)3-5-9/h10H,2-5H2,1H3

Upstream product

• 1445-73-4 1-Methyl-4-piperidone 
• 151-50-8 potassium cyanide 
• 7664-41-7 ammonia 
• 143-33-9 sodium cyanide 
• 34737-83-2 1-methylpiperidin-4-one hydrochloride 

Downstream Products

• 168818-61-9 4-hydroxy-4-carbamoyl-1-methylpiperidine 
• 408525-94-0 4-(α-hydroxy-benzhydryl)-1-methyl-piperidin-4-ol 
• 6636-28-8 1-methyl-5,5-diphenyl-hexahydro-azepin-4-one 

Relevant academic research and scientific papers

AZA SPIRO COMPOUNDS ACTING ON THE CHOLINERGIC SYSTEM WITH MUSCARINIC AGONIST ACTIVITY

Compounds useful for treating diseases of the central or peripheral nervous system in mammals have formulae I-XII STR1 wherein ring A or A' together with the spiro-carbon atom constitutes a bridged or unbridged ring containing one or two ring nitrogen atoms; and the other symbols have specified values, subject to certain conditions.

Spiro compounds containing five-membered rings

Compounds useful for treating diseases of the central or peripheral nervous system in mammals have formulae I-XIII: STR1 wherein ring A or A' together with the spiro-carbon atom constitutes a bridged or unbridged ring containing one or two ring nitrogen atoms; and the other symbols have specified values, subject to certain conditions.

Novel 5-HT3 antagonists: Indol-3-ylspiro(azabicycloalkane-3,5'(4'H)- oxazoles)

The synthesis and biochemical evaluation of a series of spirofused indole oxazoline 5-HT3 antagonists is described in which the oxazoline ring acts as a bioisosteric replacement for esters and amides. The effect of substitution about the indole ring has shown the steric limitations of the aromatic binding site. Incorporation of a variety of azabicyclic systems within the rigid spirofused framework has allowed the definition of a binding model which incorporates a number of known antagonists and agonists. In this model steric constraints limit substitution around the indole ring although there is some bulk tolerance at the 1- and 2-positions. The importance of constraining the basic nitrogen within an azabicyclic system is underlined by comparison with the monocyclic piperidine. The highest affinity was observed for those compounds in which the basic nitrogen occupies a bridgehead position, the most potent analogue in this group being the azabicyclic [3.3.1] system (pIC50 = 8.95), suggesting lipophilic interactions may play a role in increasing affinity. A suggested model for agonist binding is included in which the basic nitrogens are superimposed and the 5-hydroxyl group of 5-HT is superimposed on the H-bond-accepting atom of the heterocyclic linking group.

2-Amino-5-spiro substituted oxazoline-4-one compounds

A novel series of 2-amino-5-spiro substituted oxazolin-4-ones and intermediates for making said compounds. These compounds are prepared by first converting the appropriately substituted cycloketone to the corresponding cyclocyanohydrin; converting this co